Elena Morozova, MD, PhD, RM Gorbacheva Research Institute, Pavlov University, St. Petersburg, Russian Federation, discusses the clinical need and challenges of performing allogeneic hemopoietic stem cell transplants (allo-HSCT) in patients with advanced phase chronic myeloid leukemia (CML). Dr Morozova goes on to highlight the findings of a comparative study in which patients that received allo-HSCT had significantly improved four-year overall survival (OS) as compared to the non-transplanted group. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.